AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Report Publication Announcement Mar 8, 2023

7612_rns_2023-03-08_0e9e35fb-6d43-407e-bf7d-e0aaae1916d2.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 1918S

Eco Animal Health Group PLC

08 March 2023

ECO Animal Health Group plc

(''ECO" or "the Group")

(AIM: EAH)

Animal Health, Nutrition & Technology Innovation

ECO Animal Health Group plc ("ECO" or "the Group"), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that it will be participating at the Animal Health, Nutrition and Technology Innovation summit and leading the round table discussion on swine disease management.

Animal Health, Nutrition and Technology Innovation Europe is the sector's premier innovation summit, showcasing the emerging companies and connecting them with investors and strategic partners. The summit engages all key participants in the value chain so it can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.

Please find further information on the event at https://kisacoresearch.com/events/animal-health-europe-2023

Contacts:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)
020 8447 8899
IFC Advisory

Graham Herring

Zach Cohen
020 3934 6630
Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

George Tzimas
020 7496 3000
Investec (Joint Broker)

Gary Clarence

Daniel Adams

Carlo Spingardi
020 7597 5970
Equity Development

Hannah Crowe

Matt Evans
020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUBRVROUUORAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.